Table 4.

Immunization schedules of U.S. FDA-licensed higher-valent combination vaccines

Vaccine	Trade name (year licensed)	Age range	Routinely recommended ages
DTaP-IPV	Kinrix (2008)	4–6 years	5th dose of DTaP, and 4th dose of IPV between 4 and 6 years of age
DTaP-IPV	Quadracel (2015)	4–6 years	5th dose of DTaP, and 4th or 5th dose of IPV between 4 and 6 years of age
DTaP-IPV-Hib	Pentacel (2008)	6 weeks–4 years	4-dose series at 2, 4, 6, and 15–18 months of age
DTaP-HepB-IPV	Pediarix (2002)	6 weeks–6 years	3-dose series at 2, 4, and 6 months of age
DTaP-IPV-Hib-HepB	Vaxelis (2018)	6 weeks–4 years	3-dose series at 2, 4, and 6 months of age

DTaP-IPV Diphtheria, tetanus, acellular pertussis, and polio; DTaP-IPV-Hib Diphtheria, tetanus, acellular pertussis, polio, and Haemophilus influenzae type b; DTaP-HepB-IPV Diphtheria, tetanus, acellular pertussis, hepatitis B, and polio; DTaP-IPV-Hib-HepB Diphtheria, tetanus, acellular pertussis, polio, Haemophilus influenzae type b, and hepatitis B